Mazen Jamous1, Maria L Tamma1, Eleni Gourni2, Beatrice Waser3, Jean C Reubi3, Helmut R Maecke4, Rosalba Mansi5. 1. Division of Radiological Chemistry, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland. 2. Department of Nuclear Medicine, University Hospital Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany. 3. Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Murtenstrasse 31, CH-3010 Berne, Switzerland. 4. Division of Radiological Chemistry, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland; Department of Nuclear Medicine, University Hospital Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany. 5. Division of Radiological Chemistry, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland; Department of Nuclear Medicine, University Hospital Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany. Electronic address: rosalba.mansi@uniklinik-freiburg.de.
Abstract
INTRODUCTION: The gastrin-releasing peptide receptor (GRPR) was shown to be expressed with high density on several types of cancers. Radiolabeled peptides for imaging and targeted radionuclide therapy have been developed. In this study, we evaluated the potential of statine-based bombesin antagonists, conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) through oligoethyleneglycol spacers, labeled with (177)Lu and we determined the effect of polyethyleneglycol (PEG) spacer length on in vitro and in vivo properties. METHODS: The bombesin antagonists were synthesized on solid phase using Fmoc chemistry; the spacers Fmoc-dPEGx-OH (x=2, 4, 6 and 12) and the DOTA(tBu)3 were coupled using a standard procedure. The peptides were labeled with (177)Lu and evaluated in vitro (lipophilicity, serum stability, internalization and binding affinity assays). Biodistribution studies were performed in PC-3 tumor-bearing nude mice. RESULTS: The solid-phase synthesis was straightforward with an overall yield ranging from 30% to 35% based on the first Fmoc cleavage. The hydrophilicity increased with spacer length (logD: -1.95 vs -2.22 of PEG2 and PEG12 analogs, respectively). There is a tendency of increased serum stability by increasing the spacer length (T1/2=246±4 and 584±20 for PEG2 and PEG6 analogs, respectively) which seems to reverse with the PEG12 analog. The IC50 values are similar with the only significant difference of the PEG12 analog. The (177)Lu-labeled PEG4 and PEG6 conjugates showed similar pharmacokinetic with high tumor uptake and excellent tumor-to-kidney ratios (7.8 and 9.7 at 4h for the PEG4 and PEG6 derivatives, respectively). The pancreas uptake was relatively high at 1h but it shows fast washout (0.46%±0.02% IA/g and 0.29%±0.08% IA/g already at 4h). CONCLUSION: Among all the studied analogs the PEG4 and PEG6 showed significantly better properties. The very high tumor-to-non-target organ ratios, in particular tumor-to-kidney ratios, already at early time point will be important in regard to safety concerning kidney toxicity.
INTRODUCTION: The gastrin-releasing peptide receptor (GRPR) was shown to be expressed with high density on several types of cancers. Radiolabeled peptides for imaging and targeted radionuclide therapy have been developed. In this study, we evaluated the potential of statine-based bombesin antagonists, conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) through oligoethyleneglycol spacers, labeled with (177)Lu and we determined the effect of polyethyleneglycol (PEG) spacer length on in vitro and in vivo properties. METHODS: The bombesin antagonists were synthesized on solid phase using Fmoc chemistry; the spacers Fmoc-dPEGx-OH (x=2, 4, 6 and 12) and the DOTA(tBu)3 were coupled using a standard procedure. The peptides were labeled with (177)Lu and evaluated in vitro (lipophilicity, serum stability, internalization and binding affinity assays). Biodistribution studies were performed in PC-3 tumor-bearing nude mice. RESULTS: The solid-phase synthesis was straightforward with an overall yield ranging from 30% to 35% based on the first Fmoc cleavage. The hydrophilicity increased with spacer length (logD: -1.95 vs -2.22 of PEG2 and PEG12 analogs, respectively). There is a tendency of increased serum stability by increasing the spacer length (T1/2=246±4 and 584±20 for PEG2 and PEG6 analogs, respectively) which seems to reverse with the PEG12 analog. The IC50 values are similar with the only significant difference of the PEG12 analog. The (177)Lu-labeled PEG4 and PEG6 conjugates showed similar pharmacokinetic with high tumor uptake and excellent tumor-to-kidney ratios (7.8 and 9.7 at 4h for the PEG4 and PEG6 derivatives, respectively). The pancreas uptake was relatively high at 1h but it shows fast washout (0.46%±0.02% IA/g and 0.29%±0.08% IA/g already at 4h). CONCLUSION: Among all the studied analogs the PEG4 and PEG6 showed significantly better properties. The very high tumor-to-non-target organ ratios, in particular tumor-to-kidney ratios, already at early time point will be important in regard to safety concerning kidney toxicity.
Authors: Antonella Accardo; Filippo Galli; Rosalba Mansi; Luigi Del Pozzo; Michela Aurilio; Anna Morisco; Paola Ringhieri; Alberto Signore; Giancarlo Morelli; Luigi Aloj Journal: EJNMMI Res Date: 2016-02-20 Impact factor: 3.138
Authors: Livia Elena Chilug; Dana Niculae; Radu Anton Leonte; Alexandrina Nan; Rodica Turcu; Cosmin Mustaciosu; Radu Marian Serban; Vasile Lavric; Gina Manda Journal: Molecules Date: 2020-07-24 Impact factor: 4.411
Authors: Nancy M Okuda-Shinagawa; Yulia E Moskalenko; Helena C Junqueira; Maurício S Baptista; Carlos M Marques; M Terêsa Machini Journal: ACS Omega Date: 2017-11-20
Authors: Ayman Abouzayed; Sara S Rinne; Hamideh Sabahnoo; Jens Sörensen; Vladimir Chernov; Vladimir Tolmachev; Anna Orlova Journal: Pharmaceutics Date: 2021-01-30 Impact factor: 6.321
Authors: Panagiotis Kanellopoulos; Emmanouil Lymperis; Aikaterini Kaloudi; Marion de Jong; Eric P Krenning; Berthold A Nock; Theodosia Maina Journal: Molecules Date: 2020-07-28 Impact factor: 4.411
Authors: Alice D'Onofrio; Francisco Silva; Lurdes Gano; Urszula Karczmarczyk; Renata Mikołajczak; Piotr Garnuszek; António Paulo Journal: Front Med (Lausanne) Date: 2021-06-11